Structure-Function Analyses of Single Nucleotide Polymorphisms in Human N-Acetyltransferase 1

REFERENCES

• Adam P. J., Berry J., Loader J. A., Tyson K. L., Craggs G., Smith P., De Belin J., Steers G., Pezzella F., Sachsenmeir K. F., Stamps A. C., Herath A., Sim E., O'Hare M. J., Harris A. L., Terrett J. A. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol. Cancer Res. 2003; 1: 826–835
   PubMed Web of Science ®Google Scholar
• Ambrosone C. B., Abrams S. M., Gorlewska-Roberts K., Kadlubar F. F. Hair dye use, meat intake, and tobacco exposure and presence of carcinogen-DNA adducts in exfoliated breast ductal epithelial cells. Arch. Biochem. Biophys. 2007; 464: 169–175
   PubMed Web of Science ®Google Scholar
• Bell D. A., Stephens E. A., Castranio T., Umbach D. M., Watson M., Deakin M., Elder J., Hendrickse C., Duncan H., Strange R.C. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995; 55: 3537–3542
   PubMed Web of Science ®Google Scholar
• Bieche I., Girault I., Urbain E., Tozlu S., Lidereau R. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res. 2004; 6: 2252–2263
   Web of Science ®Google Scholar
• Boukouvala S., Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug. Metab. Rev. 2005; 37: 511–564
   PubMed Web of Science ®Google Scholar
• Bruhn C., Brockmoller J., Cascorbi I., Roots I., Borchert H. H. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem. Pharmacol. 1999; 58: 1759–1764
   PubMed Web of Science ®Google Scholar
• Butcher N. J., Arulprgasam A., Minchin R. F. Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine. J. Biol. Chem. 2004; 279: 22131–22137
   PubMed Web of Science ®Google Scholar
• Carmichael S. L., Shaw G. M., Yang W., Iovannisci D. M., Lammer E. Risk of limb deficiency defects associated with NAT1, NAT2, GSTT1, GSTM1, and NOS3 genetic variants, maternal smoking, and vitamin supplement intake. Am. J. Med. Genet. A. 2006; 140: 1915–1922
   PubMed Web of Science ®Google Scholar
• Chen J., Stampfer M. J., Hough H. L., Garcia-Closas M., Willett W. C., Hennekens C. H., Kelsey K. T., Hunter D. J. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res. 1998; 58: 3307–3311
   PubMed Web of Science ®Google Scholar
• de Leon J. H., Vatsis K. P., Weber W. W. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol. Pharmacol. 2000; 58: 288–299
   PubMed Web of Science ®Google Scholar
• Doll M. A., Jiang W., Deitz A. C., Rustan T. D., Hein D. W. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem. Biophys. Res. Commun. 1997; 233: 584–591
   PubMed Web of Science ®Google Scholar
• Dupret J. M., Grant D. M. Site-directed mutagenesis of recombinant human arylamine N‐acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J. Biol. Chem. 1992; 267: 7381–7385
   PubMed Web of Science ®Google Scholar
• Fretland A. J., Doll M. A., Leff M. A., Hein D. W. Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics 2001; 11: 511–520
   PubMedGoogle Scholar
• Fretland A. J., Doll M. A., Zhu Y., Smith L., Leff M. A., Hein D. W. Effect of nucleotide substitutions in N-acetyltransferase 1 N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: implications for cancer predisposition. Cancer Detect. Prev. 2002; 26: 10–14
   PubMedGoogle Scholar
• Gago-Dominguez M., Bell D. A., Watson M. A., Yuan J. M., Castelao J. E., Hein D. W., Chan K. K., Coetzee G. A., Ross R. K., Yu M. C. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis 2003; 24: 483–489
   PubMed Web of Science ®Google Scholar
• Gemignani F., Landi S., Szeszenia-Dabrowska N., Zaridze D., Lissowska J., Rudnai P., Fabianova E., Mates D., Foretova L., Janout V., Bencko V., Gaborieau V., Gioia-Patricola L., Bellini I., Barale R., Canzian F., Hall J., Boffetta P., Hung R.J., Brennan P. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007; 28: 1287–1293
   PubMed Web of Science ®Google Scholar
• Goodfellow G. H., Dupret J. M., Grant D. M. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem. J. 2000; 348: 159–166
   PubMed Web of Science ®Google Scholar
• Hein D. W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 2002; 506–507, 65–77.
   Web of Science ®Google Scholar
• Hein D. W., Leff M. A., Ishibe N., Sinha R., Frazier H. A., Doll M. A., Xiao G. H., Weinrich M. C., Caporaso N. E. Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ. Mol. Mutagen. 2002; 40: 161–167
   PubMed Web of Science ®Google Scholar
• Hubbard S. J., Thornton J. M. ‘NACCESS’, Computer Program, Department of Biochemistry and Molecular Biology. University College London. 1993
   Google Scholar
• Hughes N. C., Janezic S. A., McQueen K. L., Jewett M. A., Castranio T., Bell D. A., Grant D. M. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998; 8: 55–66
   PubMedGoogle Scholar
• Ishibe N., Sinha R., Hein D. W., Kulldorff M., Strickland P., Fretland A. J., Chow W. H., Kadlubar F. F., Lang N. P., Rothman N. Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 2002; 12: 145–150
   PubMedGoogle Scholar
• Jensen L. E., Hoess K., Mitchell L. E., Whitehead A.S. Loss of function polymorphisms in NAT1 protect against spina bifida. Hum. Genet. 2006; 120: 52–57
   PubMed Web of Science ®Google Scholar
• Jiao L., Doll M. A., Hein D. W., Bondy M. L., Hassan M. M., Hixson J. E., Abbruzzese J. L., Li D. Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 2379–2386
   PubMed Web of Science ®Google Scholar
• Katoh T., Inatomi H., Yang M., Kawamoto T., Matsumoto T., Bell D. A. Arylamine N‐acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics 1999; 9: 401–404
   PubMedGoogle Scholar
• Kawamura A., Graham J., Mushtaq A., Tsiftsoglou S. A., Vath G. M., Hanna P. E., Wagner C. R., Sim E. Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem. Pharmacol. 2005; 69: 347–359
   PubMed Web of Science ®Google Scholar
• Lammer E. J., Shaw G. M., Iovannisci D. M., Finnell R. H. Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N-transferase 1 (NAT1), and risk for orofacial clefts. Birth Defects Res. A. Clin. Mol. Teratol. 2004a; 70: 846–852
   PubMed Web of Science ®Google Scholar
• Lammer E. J., Shaw G. M., Iovannisci D. M., Van Waes J., Finnell R. H. Maternal smoking and the risk of orofacial clefts: Susceptibility with NAT1 and NAT2 polymorphisms. Epidemiology 2004b; 15: 150–156
   PubMed Web of Science ®Google Scholar
• Lau E. Y., Felton J. S., Lightstone F. C. Insights into the o-acetylation reaction of hydroxylated heterocyclic amines by human arylamine N-acetyltransferases: a computational study. Chem. Res. Toxicol. 2006; 19: 1182–1190
   PubMed Web of Science ®Google Scholar
• Lee K. M., Park S. K., Kim S. U., Doll M. A., Yoo K. Y., Ahn S. H., Noh D. Y., Hirvonen A., Hein D. W., Kang D. N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer. Cancer Lett. 2003; 196: 179–186
   PubMed Web of Science ®Google Scholar
• Li D., Jiao L., Li Y., Doll M. A., Hein D. W., Bondy M. L., Evans D. B., Wolff R. A., Lenzi R., Pisters P. W., Abbruzzese J. L., Hassan M. M. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006; 27: 103–111
   PubMed Web of Science ®Google Scholar
• Lilla C., Verla-Tebit E., Risch A., Jager B., Hoffmeister M., Brenner H., Chang-Claude J. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer. Epidemiol. Biomarkers Prev. 2006; 15: 99–107
   PubMed Web of Science ®Google Scholar
• Liu L., Von Vett A., Zhang N., Walters K. J., Wagner C. R., Hanna P. E. Arylamine N‐acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2. Chem. Res. Toxicol. 2007; 20: 1300–1308
   PubMed Web of Science ®Google Scholar
• Liu F., Zhang N., Zhou X., Hanna P. E., Wagner C. R., Koepp D. M., Walters K. J. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J. Mol. Biol. 2006; 361: 482–492
   PubMed Web of Science ®Google Scholar
• McDonald I. K., Thornton J. M. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 1994; 238: 777–793
   PubMed Web of Science ®Google Scholar
• Millikan R. C., Pittman G. S., Newman B., Tse C. K., Selmin O., Rockhill B., Savitz D., Moorman P. G., Bell D. A. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 371–378
   PubMed Web of Science ®Google Scholar
• Minchin R. F., Hanna P. E., Dupret J. M., Wagner C. R., Rodrigues-Lima F., Butcher N. J. Arylamine N-acetyltransferase I. Int. J. Biochem. Cell. Biol. 2007; 39: 1999–2005
   PubMed Web of Science ®Google Scholar
• Morton L. M., Bernstein L., Wang S. S., Hein D. W., Rothman N., Colt J. S., Davis S, Cerhan J. R., Severson R. K., Welch R., Hartge P., Zahm S. H. Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. Carcinogenesis 2007; 28: 1759–1764
   PubMed Web of Science ®Google Scholar
• Morton L. M., Schenk M., Hein D. W., Davis S., Zahm S. H., Cozen W., Cerhan J. R., Hartge P., Welch R., Chanock S. J., Rothman N., Wang S. S. Genetic variation in N‐acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet. Genomics 2006; 16: 537–545
   PubMed Web of Science ®Google Scholar
• Payton M., Mushtaq A., Yu T. W., Wu L. J., Sinclair J., Sim E. Eubacterial arylamine N-acetyltransferases—identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues. Microbiology 2001; 147: 1137–1147
   PubMed Web of Science ®Google Scholar
• Pettersen E. F., Goddard T. D., Huang C. C., Couch G. S., Greenblatt D. M., Meng E. C., Ferrin T. E. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 2004; 25: 1605–1612
   PubMed Web of Science ®Google Scholar
• Rodrigues-Lima F., Dupret J. M. 3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. Biochem. Biophys. Res. Commun. 2002; 291: 116–123
   PubMed Web of Science ®Google Scholar
• Rovito P. M., Morse P. D., Spinek K., Newman N., Jones R. F., Wang C. Y., Haas G. P. Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancer. Prostate Cancer Prostatic Dis. 2005; 8: 69–74
   PubMed Web of Science ®Google Scholar
• Sanderson S., Salanti G., Higgins J. Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. Am. J. Epidemiol. 2007; 166: 741–751
   PubMed Web of Science ®Google Scholar
• Sandy J., Mushtaq A., Kawamura A., Sinclair J., Sim E., Noble M. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis—an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 2002; 318: 1071–1083
   PubMed Web of Science ®Google Scholar
• Sinclair J. C., Sandy J., Delgoda R., Sim E., Noble M. E. Structure of arylamine N‐acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. 2000; 7: 560–564
   PubMedGoogle Scholar
• Sorlie T., Perou C. M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Thorsen T., Quist H., Matese J. C., Brown P. O., Botstein D., Eystein Lonning P., Borresen-Dale A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001; 98: 10869–10874
   PubMed Web of Science ®Google Scholar
• Taylor J. A., Umbach D. M., Stephens E., Castranio T., Paulson D., Robertson C., Mohler J. L., Bell D. A. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res. 1998; 58: 3603–3610
   PubMed Web of Science ®Google Scholar
• Wakefield L., Cornish V., Long H., Griffiths W. J., Sim E. Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism. Biochem. Biophys. Res. Comm. 2007; 364: 556–560
   PubMed Web of Science ®Google Scholar
• Walraven J. M., Trent J.O., Hein D.W. Computational and experimental analyses of mammalian arylamine N-acetyltransferase structure and function. Drug Metab. Dispos. 2007; 35: 1001–1007
   PubMed Web of Science ®Google Scholar
• Wikman H., Thiel S., Jager B., Schmezer P., Spiegelhalder B., Edler L., Dienemann H., Kayser K., Schulz V., Drings P., Bartsch H., Risch A. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 2001; 11: 157–168
   PubMedGoogle Scholar
• Wu H., Dombrovsky L., Tempel W., Martin F., Loppnau P., Goodfellow G. H., Grant D. M., Plotnikov A. N. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J. Biol. Chem. 2007; 282: 30189–30197
   PubMed Web of Science ®Google Scholar
• Zhangwei X., Jianming X., Qiao M., Xinhua X. N-Acetyltransferase-1 gene polymorphisms and correlation between genotype and its activity in a central Chinese Han population. Clin. Chim. Acta 2006; 371: 85–91
   PubMed Web of Science ®Google Scholar
• Zheng W., Deitz A. C., Campbell D. R., Wen W. Q., Cerhan J. R., Sellers T. A., Folsom A. R., Hein D. W. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 233–239
   PubMed Web of Science ®Google Scholar
• Zhu Y., Hein D.W. Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenomics J. 2007, 10.1038/sj.tpj.6500483.
   PubMed Web of Science ®Google Scholar